- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00157092
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
April 29, 2021 updated by: Baxalta now part of Shire
A Phase 1B/2A Study to Evaluate the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
The study was a Phase 1B/2A, uncontrolled, open-label, single-center study in individuals with congenital AAT (alpha 1-antitrypsin) deficiency.
A baseline bronchoscopy with bronchoalveolar lavage (BAL) was performed 3 to a maximum of 4 weeks prior to the first administration of study drug.
Fifteen eligible subjects were randomized to receive 1 of 3 dosing regimens of rAAT (100 mg daily, 100 mg twice daily, or 200 mg daily) administered via nebulization for 7 consecutive days.
A post-treatment nadir BAL was obtained on study Day 8 (12 hours after last dose for subjects who receive drug therapy twice daily and 24 hours after the last dose for subjects who receive study product daily).
BALs were conducted in the same lung lobe/segment.
Follow-up visits took place on Day 15 and Day 36.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Shands Hospital at the University of Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed Informed Consent
- Male or female 18 years of age or older
- Documented, endogenous plasma AAT levels < 11 µM (< 80 mg/dL), either obtained from the medical history or, if not documented, plasma AAT measured after 28 day washout of any prior replacement therapy
- Forced expiratory volume at 1 second (FEV1) that is >= 50% of predicted, measured 30 minutes after a short-acting inhaled bronchodilator
- Arterial oxygen percent saturation (SaO2, measured using room air) within the normal limits for the individual study site
- For subjects receiving an inhaled corticosteroid, inhaled or oral β-2 agonist (e.g., albuterol via metered dose inhaler [MDI]) or inhaled anticholinergic bronchodilator (e.g., ipratropium bromide), or oral PDE (phosphodiesterase) inhibitor, treatment on a stable dose for at least 14 days prior to enrollment
- For any female of childbearing potential, a negative urine test for pregnancy within 3 days prior to enrollment and agreement to employ adequate birth control measures for the duration of the study
- No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed at the screening visit
- Laboratory results obtained at the screening visit, meeting the following criteria:
- Serum aspartate transaminase (AST) and alanine transaminase (ALT) <= 2 times upper limit of normal range (ULN)
- Serum total bilirubin <= 2 times ULN
- < 2+ proteinuria on urine dipstick
- Serum creatinine <= 1.5 times ULN
- Absolute neutrophil count >= 1500 cells/mm3
- Hemoglobin >= 10.0 g/dL
- Platelet count >= 100,000/mm3
Exclusion Criteria:
- Clinically significant pulmonary impairment, other than emphysema and/or chronic bronchitis
- Moderate to severe bronchiectasis
- Clinically significant cardiac, hemostatic, or neurologic impairment, or other significant medical condition that, in the opinion of the investigator, would affect subject safety or compliance
- Psychiatric or cognitive disturbance or illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance
- Acute exacerbation of emphysema within 28 days prior to the screening visit
- Pregnancy or lactation
- Known history of allergy to yeast products
- Medical history precluding the use of epinephrine or other rescue medication for treatment of anaphylaxis
- Prior history of adverse reactions to the local anesthetic, sedative, BAL procedure, or pre-medication employed at the study center
- Use of oral or parenteral glucocorticosteroids, or alpha 1-antitrypsin replacement therapy within 28 days prior to baseline BAL, or any use planned during the study. However, the subject may enroll provided that a) consent is given to undergo a 28-day washout of the replacement or steroid therapy, and b) no study procedures are done until the washout is completed.
- Use of another investigational drug or investigational device within 28 days prior to baseline BAL
- Any upper or lower respiratory infection within 28 days prior to baseline BAL
- Having received a lung or liver transplant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Alpha 1-antitrypsin levels assessed from epithelial lining fluid (ELF) samples
Time Frame: Baseline (minimum of 3 to a maximum of 4 weeks prior to the first administration of study product).
|
Baseline (minimum of 3 to a maximum of 4 weeks prior to the first administration of study product).
|
Alpha 1-antitrypsin levels assessed from epithelial lining fluid (ELF) samples
Time Frame: Day 8 after the first administration of study product
|
Day 8 after the first administration of study product
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2004
Primary Completion (Actual)
October 14, 2004
Study Completion (Actual)
October 14, 2004
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Actual)
May 5, 2021
Last Update Submitted That Met QC Criteria
April 29, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Subcutaneous Emphysema
- Emphysema
- Alpha 1-Antitrypsin Deficiency
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Serine Proteinase Inhibitors
- Trypsin Inhibitors
- Alpha 1-Antitrypsin
- Protein C Inhibitor
Other Study ID Numbers
- 410302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alpha1-antitrypsin Deficiency
-
Grifols Therapeutics LLCGrifols Japan K.K.CompletedAlpha1-Antitrypsin DeficiencyJapan
-
Baxalta now part of ShireArriva Pharmaceuticals, Inc.CompletedAlpha1-antitrypsin DeficiencyUnited States
-
TakedaEnrolling by invitationAlpha1-Antitrypsin DeficiencyUnited Kingdom, Germany, United States, Austria, Portugal
-
Baxalta now part of ShireCompleted
-
RWTH Aachen UniversityUnknown
-
Grifols Therapeutics LLCRecruiting
-
Vertex Pharmaceuticals IncorporatedCompletedAlpha1-Antitrypsin DeficiencyUnited States, Germany, Canada, Ireland, Sweden, United Kingdom
-
Grifols Therapeutics LLCGrifols Japan K.K.Completed
-
Baxalta now part of ShireCompletedAlpha1-antitrypsin DeficiencyUnited States, Canada
-
Baxalta now part of ShireTerminated
Clinical Trials on Aerosolized, Recombinant Alpha 1-Antitrypsin
-
Baxalta now part of ShireArriva Pharmaceuticals, Inc.CompletedAlpha1-antitrypsin DeficiencyUnited States
-
Kamada, Ltd.Completed
-
Kamada, Ltd.CompletedType 1 Diabetes MellitusIsrael
-
Rabin Medical CenterUnknownLung Transplantation | Bronchiolitis Obliterable Syndrome
-
Kamada, Ltd.CompletedNew Onset Type-1 DiabetesIsrael
-
University of Colorado, DenverOmni Bio Pharmaceutical, Inc.CompletedDiabetes | Type 1 DiabetesUnited States
-
Impatients N.V. trading as myTomorrowsKamada, Ltd.No longer availableAlpha 1-Antitrypsin Deficiency | Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Steroid Refractory Acute Graft Versus Host Disease | Alpha-1 Proteinase Inhibitor | Alpha-1 Protease Inhibitor Deficiency | Acute Graft-Versus-Host Reaction Following Bone Marrow...
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingSarcoma | Metastatic Melanoma | Metastatic Renal Cell Cancer | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IV Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Malignant Neoplasm in the LungUnited States
-
CSL BehringRecruitingAcute-graft-versus-host DiseaseUnited States, Korea, Republic of, Spain, Australia, Germany, Italy, Turkey, Japan
-
Michael Campos, MDCSL BehringCompletedAlpha 1 Antitrypsin DeficiencyUnited States